CCLA Investment Management Purchases 275 Shares of Johnson & Johnson $JNJ

CCLA Investment Management raised its position in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,146 shares of the company’s stock after buying an additional 275 shares during the quarter. CCLA Investment Management’s holdings in Johnson & Johnson were worth $3,991,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after buying an additional 1,170,120 shares during the period. Northern Trust Corp raised its holdings in Johnson & Johnson by 0.4% during the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after acquiring an additional 130,645 shares during the period. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Johnson & Johnson by 3.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after acquiring an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in Johnson & Johnson by 2.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after acquiring an additional 448,666 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Trading Down 1.1%

Shares of JNJ stock opened at $190.38 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The company has a market capitalization of $458.69 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The business’s fifty day moving average is $182.26 and its 200 day moving average is $166.37.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.